Prospective Clinical Study of ¹²⁵I Particle Permanent Implantation for Prostate Cancer

Abstract

Objective: To investigate the clinical effect of 125 I radioactive seed implantation and the treatment of prostate cancer with radical resection of prostate cancer. Methods: Within the period of the second phase, 62 cases of prostate cancer patients, aged from 46 to 87 years old, average 69 years old. In the treatment group, 30 cases were implanted with 125 I radioactive particles via the rectum with the guidance of the rectum. 32 cases in the control group underwent radical prostatectomy. Results: All patients were operated successfully, the patients were followed up for 12 to 36 months. In the treatment group, the average particle size was 38 + 15. No serious complications caused by rectal puncture. 2 patients occurred 6 months after PSA increased significantly, systemic examination revealed bone metastases, and underwent endocrine therapy. In the control group, there were 2 cases of patients with PSA significantly increased in 5 months after surgery, and the external irradiation plus endocrine therapy. During the observation period, the survival rate of the patients who were implanted with 125 I particles in the treatment group without progression was 93.3%. Control group, the cumulative PSA progression free survival rate was 93.7%. Conclusion: Patients with prostate cancer during the second phase, the clinical curative effect of the treatment of prostate cancer with the treatment of 125 I of prostate cancer and the treatment of prostate cancer by using radical resection of prostate cancer are quite. This technology has the advantages of small trauma, quick recovery, low damage to normal tissue.